Filed by Social Capital Suvretta Holdings Corp. I
pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934
Subject Company: Akili Interactive Labs, Inc.
Registration No.: 333-262706
Date: August 1, 2022
This filing relates to
the proposed merger of Akili Interactive Labs, Inc., a Delaware corporation (Target), with Karibu Merger Sub, Inc. (Merger Sub), a Delaware corporation and a wholly owned subsidiary of Social Capital Suvretta Holdings Corp.
I, a Cayman Islands exempted company limited by shares (SPAC), pursuant to the terms of that certain Agreement and Plan of Merger, dated as of January 26, 2022, by and among SPAC, Merger Sub and Target.
Shionogi Begins Phase 3 Study in Japan of Akilis Digital Treatment in Children with ADHD
Pivotal study follows successful Phase 2 trial, which demonstrated improvements in attention function as compared to both treatment as usual
and single task video game groups
Pivotal Data Readout expected in 2H2023
BOSTON, Mass. August 1, 2022 Akili Interactive (Akili), a leading digital medicine company, today
announced the start of a pivotal Phase 3 randomized, controlled study of SDT-001 (a version of AKL-T01 localized for Japanese language and culture), a product candidate
designed to improve measures of attention in children diagnosed with attention-deficit/hyperactivity disorder (ADHD). The study, conducted by Akilis partner, global pharmaceutical company Shionogi & Co., Ltd.
(Shionogi), is designed to evaluate the safety and efficacy of the product candidate in children ages 6-17 with ADHD as a registration-enabling trial. Clinical trial sites have begun enrolling
patients, and results of the study are expected in 2H2023.
ADHD has a significant impact on children and their families in Asia, and caregivers and
health care providers are looking for innovative non-drug treatment options. Following our successful Phase 2 study of SDT-001, we are excited to advance Akilis
product candidate through the clinical process to potentially help the millions of children living in Japan with ADHD, said Takeki Uehara, Corporate Officer, Senior Vice President, Drug Development and Regulatory Science Division of
Shionogi & Co., Ltd.
We are thankful to our partners at Shionogi who share our commitment to patients and have initiated this pivotal
study ahead of schedule, said Anil S. Jina M.D., Chief Medical Officer of Akili. This trial is an important step towards our goal to help all eligible children with ADHD across the globe, irrespective of their language, culture, or
geographic location.